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Individual differences in schizophrenia
Edmund T. Rolls, Wenlian Lu, Lin Wan, Hao Yan, Chuanyue Wang, Fude Yang, Yunlong Tan, Lingjiang Li, 
Chinese Schizophrenia Collaboration Group, Hao Yu, Peter F. Liddle, Lena Palaniyappan, Dai Zhang, 
Weihua Yue and Jianfeng Feng
Background
Whether there are distinct subtypes of schizophrenia is an 
important issue to advance understanding and treatment of 
schizophrenia.
Aims
To understand and treat individuals with schizophrenia, the aim 
was to advance understanding of differences between individuals, 
whether there are discrete subtypes, and how first-episode 
patients (FEP) may differ from multiple episode patients (MEP).
Method
These issues were analysed in 687 FEP and 1880 MEP with 
schizophrenia using the Positive and Negative Syndrome 
Scale for (PANSS) schizophrenia before and after antipsychotic 
medication for 6 weeks.
Results
The seven Negative Symptoms were correlated with 
each other and with P2 (conceptual disorganisation), 
G13 (disturbance of volition), and G7 (motor retardation). 
The main difference between individuals was in the cluster of 
seven negative symptoms, which had a continuous unimodal 
distribution. Medication decreased the PANSS scores for 
all the symptoms, which were similar in the FEP and MEP 
groups.
Conclusions
The negative symptoms are a major source of individual 
differences, and there are potential implications for treatment.
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Previous research has indicated that schizophrenia is heterogeneous 
in clinical symptoms and time course, suggesting the possibility of 
identifying subtypes differing in cause and/or pathological mecha-
nism.1 The identification of subtypes could facilitate investigation 
of cause and mechanism, including the use of genetic and neuro-
science approaches.2–5 Many approaches consider that there are 
positive symptoms (including hallucinations and delusions), neg-
ative symptoms (including low mood, motivation, and emotion), 
and cognitive symptoms, including poor attention.6–8 It has been 
suggested that at least in chronic cases, the positive symptoms split 
into two subgroups: reality distortion and disorganisation.7,9 Many 
studies that have included a wider range of symptoms have found 
evidence for five clusters of symptoms, namely, reality distortion, 
disorganisation, negative symptoms, depression and excitation (re-
viewed by Peralta & Cuesta).10
In order to better understand and treat individuals with schizo-
phrenia, the aims of the present investigation were to understand 
differences between individuals with schizophrenia; whether there 
are discrete subtypes of schizophrenia; how first-episode patients 
(FEP) may differ from multiple episode patients (MEP) and how 
medication influences the symptoms. Two approaches to delineat-
ing the heterogeneity of schizophrenia were taken. One approach 
was an examination of the pattern of correlation between symp-
toms to identify underlying symptom communities (or dimen-
sions), presumed to reflect specific pathological processes. Another 
approach was an examination of the correlations between patients, 
to identify communities of patients (subtypes) each characterised 
by a symptom profile reflecting a particular combination of symp-
tom dimensions. In the main text, we employ the standard and 
well-established hierarchical clustering method using k-means.11 
In the supplement, we present qualitatively similar results obtained 
using a powerful community detection algorithm based on the 
concept of modularity described by Newman & Girvan,12 which 
was also useful in providing an estimate of the optimum number 
of communities.
Method
Participants and clinical assessment
Two samples comprising a total of 2567 patients with schizophrenia 
were diagnosed according to DSM-IV criteria.13 The first sample in-
cluded 687 FEP and drug-naive patients with schizophrenia. The 
second study sample included 1880 multi-episode patients (MEP) 
with schizophrenia with average duration of illness 7.97 years. The 
patients were recruited from in-patients from four research cent-
res (the Sixth Hospital of Peking University, the Second Xiangya 
Hospital of Central South University, Beijing Anding Hospital and 
Beijing HuiLongGuan Hospital) with institutional approval of the 
investigation and informed consent of the patients.
The symptoms were assessed by trained researchers with the 
30-item Positive and Negative Syndrome Scale for schizophrenia 
(PANSS).14 For reference, in PANSS, positive symptoms P1–P7 are 
Items 1–7, the negative symptoms N1–N7 are Items 8–14 and the 
general symptoms G1–G16 are Items 15–30. In the figures, unless 
otherwise stated, the symptoms are presented in this order, 1–30, 
with the symptoms listed in the legend to Fig. 1a. The PANSS was 
measured first in each of these patients when they were not receiv-
ing drug treatment. Then the patients were provided with one out 
of the seven randomly assigned drugs (risperidone, quetiapine, 
perphenazine, olanzapine, haloperidol, aripiprazole and ziprasi-
done) for a 6-week treatment period, and then the PANSS scores 
were measured again. This design with the same patients assessed 
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before and after medication allowed measurement of the PANSS 
when untreated, and also enabled the effects of the medication to 
be assessed using exactly the same patients. Further details of the 
patient populations and the medication used are provided in the 
Data supplement.
Statistical analysis
The data consisted for the MEP group of 1880 patient×30 symp-
tom matrix, and for the FEP group of a 687 patient×30 symptom 
matrix, for the unmedicated pre-treatment state. Corresponding 
matrices were available for the post-treatment state, providing the 
symptoms in the same patients after 6 weeks of treatment. The 
methods included calculating the symptom correlation matrix and 
the population correlation matrix. We also examined whether there 
were discrete populations of patients using the k-means clustering 
method (performed on the population correlation matrix), and 
then analysed the symptoms in the sub-populations that were de-
tected. We also investigated the distributions of symptoms across 
the patient sub-populations.
The data were analysed using the k-means cluster analysis 
algorithms that are a well-accepted approach standardised for 
availability within Matlab, using the distance measure based on 
correlations. This analysis was complemented by a modern com-
munity detection method described in the Data supplement, which 
has the advantage that it can automatically provide an indication 
of the optimal number of subgroups or communities into which 
to cluster the data.15,16 The k-means approach was the method used 
for analysis described in the main text, because it is a well-known 
and understood method for clustering data, and because one major 
difference between the populations that was identified with this ap-
proach was in the negative symptoms which have a component that 
has a unimodal continuous distribution, so we did not wish to rely 
on a community detection method that might have difficulty if it 
was forced to determine the number of communities into which 
to divide the population if it contained at least in part a continuous 
distribution. However, for comparison key results with the commu-
nity detection method are provided in the Data supplement.
Results
Multi-episode group pre-treatment (MEP_Pre)
Figure 1a shows the MEP_Pre symptom correlation matrix. The 
negative symptoms (8–14) form a clear cluster. Some correlation 
between these negative symptoms and P2 (conceptual disorganisa-
tion), G11 (poor attention), G13 (disturbance of volition) and G16 
(active social avoidance) are also evident in the symptom correla-
tion matrix shown in Fig. 1a. The community detection method 
indicated that the symptoms belong to four distinguishable com-
munities (Fig. S1). Symptom community four included the majority 
of the positive symptoms (P1 P4 P5 P6 P7) and general symptoms 
(G8 G9 G12 G14). Symptom Community 1 included the majority of 
the negative symptoms (N1 N2 N3 N4 N6) and general symptoms 
(G7 G13 G16).
As shown in Fig. S2, the community detection algorithm indi-
cated that the sample contained three distinguishable communities 
of patients. The patient clusters generate by the three-cluster output 
of the k-mean algorithm had distinct symptom profiles (Fig. 1b). In 
the MEP_Pre sample, the sub-population labelled PN (positive and 
high negative symptoms, 694 cases) had high values for the negative 
symptoms (N1–N7=symptoms 8–14). The sub-population labelled 
Pn (positive and intermediate negative symptoms, 535 cases) had 
intermediate values for the negative symptoms. The sub-population 
labelled P (positive and low negative symptoms, 651 cases) had 
low values for the negative symptoms, especially N1 and N2. Little 
else differed between these clusters, except that the PN cluster had 
a higher value for P2 (conceptual disorganisation) and relatively 
small values for P1 and P3–P6; whereas the P cluster had relatively 
high scores on symptoms P1, P3–P7, G8 and G9.
These analyses provided evidence that the scores of the negative 
symptoms were an important factor that was different between the 
three populations detected with k-means, and equally by the com-
munity detection algorithm (see Data supplement Fig. S3). Fur-
thermore, Fig. 1a shows that there are moderately high correlations 
between the seven negative symptoms, N1–N7 (Symptoms 8–14). 
To investigate how the negative symptoms were distributed across 
the population of MEP patients, the population × symptom data 
matrix was sorted by the mean value of symptoms N1–N7. The re-
sult shown in Fig. 2a indicates that there is a graded distribution of 
the negative symptoms across the population of 1880 MEP patients, 
with patients at one end of the distribution having scores close to 1 
(the minimum score possible) and at the other end close to 7 (the 
maximum score possible). (In a control analysis, it was found that 
this does not apply to the positive symptoms, which are not contin-
uously graded throughout the range between scores of 1 and 7 as 
are the negative symptoms shown in Fig. 2a.)
Further evidence was then sought of whether the distribution 
of the mean score for the seven negative symptoms was continuous 
and unimodal. Figure 2b and c show that the distribution of the 
mean of the average of the negative symptom scores in the MEP_
Pre group has a unimodal distribution, in one dimension, rather 
than a bimodal or multimodal distribution. Thus the most impor-
tant way in which the three sub-populations of MEP–Pre patients 
differed was in the negative symptom scores, which are continu-
ously distributed from 1 to 7.
Multi-episode group post-treatment (MEP_Post)
The MEP_Post symptom correlation matrix showed, similarly 
to the MEP_Pre condition illustrated in Fig. 1a, that the negative 
symptoms (8–14) form a clear cluster (Fig. S5). Three sub-popu-
lation clusters were again found by the community detection al-
gorithm and the three clusters in the MEP_Post dataset that were 
detected with the k-means algorithm which had 631 patients in the 
PN cluster, 643 in the Pn cluster and 606 in the P cluster.
Figure 1c shows the average symptom values in the three pa-
tient clusters for the MEP_Post group. The group labelled PN (pos-
itive and high negative symptoms) had high values for the negative 
symptoms (N1–N7=symptoms 8–14). The group labelled Pn (posi-
tive and intermediate negative symptoms) had intermediate values 
for the negative symptoms. The group labelled P (positive and low 
negative symptoms) had low values for the negative symptoms and 
relatively low values also for the positive symptoms. It is notable 
that the scores on all or most of the symptoms have been decreased 
by the medication (Fig. 4d). Just as in the MEP_Pre condition, a 
continuously graded distribution of the negative symptoms across 
the population of 1880 MEP_Post patients was found, with patients 
at one end of the distribution having scores close to 1 (the mini-
mum score possible) and at the other end close to 7 (the maximum 
score possible).
First-episode group pre-treatment (FEP_Pre)
Figure 3a shows the FEP_Pre symptom correlation matrix. The neg-
ative symptoms (8–14) form a clear cluster.
The community detection algorithm detected three clusters or 
sub-populations of patients, and Fig. 3b shows the average symp-
tom values in the three patient clusters for the FEP_Pre group from 
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Fig. 1. (a) MEP_Pre symptom correlation matrix. The colour bar indicates the value of the Pearson correlation. In PANSS (14), P1–P7 are Symptoms 
1–7, N1–N7 are Symptoms 8–14 and G1–G16 are Symptoms 15–30. The values for each score are 1–7. The symptoms are as follows: Delusions (P1), 
Conceptual disorganisation (P2), Hallucinations (P3), Hyperactivity (P4), Grandiosity (P5), Suspiciousness/persecution (P6), Hostility (P7), Blunted affect 
(N1), Emotional withdrawal (N2), Poor rapport (N3), Passive/apathetic social withdrawal (N4), Difficulty in abstract thinking (N5), Lack of spontaneity 
and flow of conversation (N6), Stereotyped thinking (N7), Somatic concern (G1), Anxiety (G2), Guilt feelings (G3), Tension (G4), Mannerisms and 
posturing (G5), Depression (G6), Motor retardation (G7), Uncooperativeness (G8), Unusual thought content (G9), Disorientation (G10), Poor attention 
(G11), Lack of judgment and insight (G12), Disturbance of volition (G13), Poor impulse control (G14), Preoccupation (G15) and Active social avoidance 
(G16). (b) MEP_Pre average symptom values in the three patient clusters detected by k-means. (c) MEP_Post average symptom values in the three 
patient clusters detected by k-means.
the k-means analysis. The group labelled PN (positive and high 
negative symptoms) had high values for the negative symptoms 
(N1–N7=symptoms 8–14). The group labelled Pn (positive and 
intermediate negative symptoms) had intermediate values for the 
negative symptoms. The group labelled P (positive and low nega-
tive symptoms) had low values for the negative symptoms. Little 
else differed between these clusters, except that the PN cluster has 
a smaller value for P1 (delusions) and P3 (hallucinatory behaviour) 
(Symptoms 1 and 3) and has higher scores for Symptoms 27–30 
(G13–G16). The three clusters contained 228, 233 and 226 patients, 
respectively. The symptom profiles of the groups detected by the 
k-means algorithm (Fig. 3b) are very similar to the profiles of the 
corresponding groups detected by the community detection algo-
rithm (Figs. S9 and S10).
Figure 3a shows that there are moderately high correlations be-
tween the seven negative symptoms, N1–N7 (Symptoms 8–14). To 
investigate how the negative symptoms were distributed across the 
population of FEP patients, the population × symptom data ma-
trix was sorted by the mean value of Symptoms N1–N7. The result 
shown in Fig. 4a indicates that there is a graded distribution of the 
negative symptoms across the population of 687 FEP_Pre patients, 
with patients at one end of the distribution having scores close to 1 
(the minimum score possible) and at the other end close to 7 (the 
maximum score possible).
Figure 4b and c shows that the distribution of the mean of the 
average of the negative symptom scores in the FEP_Pre group has 
a unimodal distribution, in one dimension, rather than a bimodal 
or multimodal distribution. Thus the most important way in which 
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Fig. 2. (a) MEP_Pre group sorted by the average value of the negative symptoms, N1–N7 (Symptoms 8–14). The colour bar on the right shows the 
PANSS score in the range 1–7. (b) The average score for Symptoms N1–N7 shown sorted by its value in each member of the MEP_Pre population 
(green). The red plot shows the value for N1. (c) A histogram of the average score for Symptoms N1–N7 in the MEP_Pre group. 
the three sub-populations of FEP_Pre patients differed was in 
the  negative symptom scores, which are continuously distributed 
from 1 to 7.
First-episode group post-treatment (FEP_Post)
The FEP_Post symptom correlation matrix showed, similarly to the 
FEP_Pre condition illustrated in Fig. 3a, that the negative symp-
toms (8–14) form a clear cluster (Fig. S12). Three sub-population 
clusters were again found by the community detection algorithm 
(Fig. S13), and the three clusters in the FEP_Post dataset that were 
detected with the k-means algorithm had 288 patients in the PN 
cluster, 221 in the Pn cluster and 178 in the P cluster.
Figure 3c shows the average symptom values in the three pa-
tient clusters for the FEP_Post group. The group labelled PN (pos-
itive and high negative symptoms) had high values for the negative 
symptoms (N1–N7=symptoms 8–14). The group labelled Pn (yel-
low) had high scores for P1–P7 and intermediate values for the neg-
ative symptoms. The group labelled P had low values for the negative 
and positive symptoms. It is notable that the scores on all or most of 
the symptoms have been decreased by the medication (Fig. 4e). Just 
as in the FEP_Pre condition, a continuously graded distribution of 
the negative symptoms across the population of 687 FEP_Post pa-
tients was found, with patients at one end of the distribution having 
scores close to 1 (the minimum score possible) and at the other end 
close to 7 (the maximum score possible).
Effects of treatment on the PANSS scores
The effects of treatment with antipsychotic drugs on the PANSS 
symptom scores for the MEP and FEP groups are shown in Fig. 
4d and e. Interestingly, the treatment reduced almost all the 
symptoms (with smaller effects for those close to baseline). The 
effects on the symptoms were highly similar in the MEP and 
FEP groups. Moreover, the reductions in the scores of the neg-
ative symptoms for the different sub-populations PN, Pn and P 
produced by the medication were similar (making allowance for 
the fact that the pre-treatment value was different in the three 
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Fig. 3. (a) FEP_Pre symptom correlation matrix. The colour bar indicates the value of the Pearson correlation. In PANSS (14), P1–P7 are Symptoms 
1–7, N1–N7 are Symptoms 8–14 and G1–G16 are Symptoms 15–30. The values for each score are 1–7. (b) FEP_Pre average symptom values in the 
three patient clusters detected by k-means. (c) FEP_Post average symptom values in the three patient clusters detected by k-means. 
sub-populations). The treatment consisted of one out of seven 
randomly assigned drugs (risperidone, quetiapine, perphena-
zine, olanzapine, haloperidol, aripiprazole and ziprasidone) for 
a 6-week treatment period. Further details on the effects of the 
treatments are available from the authors on request and will be 
provided elsewhere.16
Comparison of MEP and FEP groups
It is evident from Fig. 4d and e that in the pre-treatment condition, 
the FEP and MEP groups had almost identical scores, and this is 
confirmed by the explicit comparison shown in Fig. S19. It is ev-
ident from Fig. 4d and e that in the post-treatment condition, the 
FEP and MEP groups had almost identical scores (though lower 
than in the pre-treatment groups), and this is confirmed by the ex-
plicit comparison shown in Fig. S20.
Community detection results
The community detection algorithm fast_mo15 and its modified 
form fast_mo_sgn16 applied to the population correlation matrix 
produced very similar results as shown in the Data supplement 
(Figs. S1–S14) to those described in the main text using k-means, 
with the main difference that the numbers of patients in the differ-
ent clusters or communities differed somewhat.
Factor analysis and multidimensional scaling on the 
symptom correlation matrices
To provide further insight into how the different PANSS symptoms 
are related to each other and how they separate from each other, 
factor analyses and multidimensional scaling were performed 
on the symptom correlation matrices, as described in the Data 
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FEP-Pre population sorted by N1-N7 symptoms
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Fig. 4. (a) FEP_Pre group sorted by the average value of the negative symptoms, N1–N7 (Symptoms 8–14). The colour bar on the right shows the 
PANSS score in the range 1–7. (b) The average score for Symptoms N1–N7 shown sorted by its value in each member of the FEP_Pre population 
(green). The red plot shows the value for N1. (c) A histogram of the average score for Symptoms N1–N7 in the FEP_Pre group. (d and e) PANSS 
symptom scores before and after treatment for (d) the MEP and (e) the FEP groups. 
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It should be noted that we did not attempt to distinguish pri-
mary from secondary negative symptoms. Our finding of a signifi-
cant correlation between the reduction in positive symptoms and 
the reduction in negative symptoms raises the possibility that a 
proportion of the negative symptoms reported in our study might 
be secondary negative symptoms which are expected to decrease 
during treatment. However, the results of an analysis of covariance 
presented in the Data supplement show that the reduction in the 
negative symptoms produced by the medication was in part inde-
pendent of the reduction in the positive symptoms.
Furthermore, it is noteworthy that we found MEP and FEP 
cases exhibited similar decreases in symptom severity during 
6-weeks treatment. In contrast, other moderately large studies have 
reported that FEP cases show a greater reduction in symptoms dur-
ing treatment than MEP cases.22 In a longitudinal study extending 
over the first 5 years of illness, Lieberman et al23 found that treat-
ment response diminished with increasing number of relapses. It is 
possible that the exclusion of participants with treatment-resistant 
illness from our MEP sample contributed to our finding of a rela-
tively large reduction of negative symptoms in MEP cases.
Further analyses showed the following
The negative symptoms (N1–N7) are moderately well correlated 
with each other (Figs 1a and 3a). As demonstrated in the Data sup-
plement, the results of applying the community detection algorithm 
fast_mo_sgn to the symptoms showed that in the MEP and FEP 
groups, both Pre- and Post-treatment, four symptom communities 
were detected (with one minor exception). One community gen-
erally included most of the positive symptoms and another com-
munity included most of the negative symptoms (Figs  S1, S5, S8 
and S12). The analysis of symptom communities identified a com-
munity of symptoms dominated by anxiety and depression (G6) in 
both FEP (Fig. S8) and MEP (Fig. S1) groups, both before and after 
treatment. This is consistent with many studies that have reported a 
depression syndrome in schizophrenia (see the review by Peralta & 
Cuesta10). Furthermore, in the MEP_Pre cases, there was a com-
munity of symptoms reflecting disorganisation of thought and be-
haviour, together with cognitive symptoms such as poor attention, 
resembling the disorganisation syndrome identified in symptom-
atic cases of chronic schizophrenia by Bilder et al 9 and Liddle.7 Fur-
ther analysis of just the negative symptoms found that they could be 
separated into three communities (N1, N2 and N4; N3 and N6; and 
N5 and N7), and that these symptom communities were all simi-
larly reduced by medication (Data supplement).
The results shown in Figs S19 and S20 show that the PANSS 
symptoms are very similar between FEP and MEP groups with-
out medication; and that the medication produces changes in both 
groups which make the FEP_Post and MEP_Post groups very 
similar after medication. These findings have major implications 
for ‘staging’ hypotheses of schizophrenia. Any ‘staging’ hypothesis 
would need to carefully factor out the effects of treatment for its re-
sults to be interpretable. It may be that very long-term patients with 
schizophrenia do show symptom differences.5 But if so, that would 
be related to the long-term nature of the disease not clearly evident 
in the MEP and FEP groups described here.
K-means cluster analysis can be used to divide the patients into 
2–4 sub-populations (with results for three sub-populations pre-
sented), which differ from each other mainly in the extent of the nega-
tive symptoms. Community detection analysis (using fast_mo_sgn)16 
(modified from15) provides a very similar set of three sub-populations 
of both the MEP and FEP group, though the numbers of patients in 
each population are not identical. To the extent that the distribution 
of the negative symptoms is in part continuous, the cluster/com-
munity detection may not imply that the sub-populations are very 
supplement. These confirm that the major source of variation be-
tween individuals with schizophrenia is in the negative symptoms.
Discussion
The results of the analysis on the datasets with 687 FEP with 
schizophrenia before treatment (FEP_Pre) and after treatment 
(FEP_Post), and 1880 MEP before treatment (MEP_Pre) and after 
treatment (MEP_Post), provide evidence that a major difference 
between patients is the extent of the negative symptoms (Figs 1–4). 
There is little evidence for very discrete populations, with instead 
a gradation in the amount of the negative symptoms found across 
the patient populations (Figs 1–4). Indeed, the distributions for the 
mean of the negative symptoms N1–N7 are unimodal (Figs 2 and 
4), so there is little support for discrete subtypes of schizophrenia, 
on the basis of PANSS scores. Indeed, when the k-means and the 
community detection algorithms did separate the patient popula-
tions into three groups, these groups were distinguished mainly by 
the amount of the negative symptoms, as illustrated in Figs 1, 3, S3, 
S4, S10 and S11. Figures 4d, e and S19 show that the PANSS symp-
toms are almost identical before treatment in the FEP and MEP 
groups. Figures 4d, e and S20 show that the PANSS symptoms are 
almost identical after treatment in the FEP and MEP groups. The 
results shown in Fig. 4d and e show that medication decreases the 
scores on essentially all PANSS symptom scores.
Our finding of a continuous unimodal distribution of negative 
symptoms is consistent with many cross-sectional studies that have 
described the heterogeneity of schizophrenia in terms of multiple 
dimensions (reviewed by Peralta & Cuesta10). Our findings indicate 
that the negative dimension plays a particularly important role in 
differentiating patients, but do not provide evidence for discrete 
subtypes of illness. However, our cross-sectional analyses do not 
address the question of whether or not taking account of persis-
tence of symptoms or treatment response might help identify dis-
crete subtypes. Some previous studies that have taken account of the 
tendency of symptoms to persist have identified a subtype of illness 
designated deficit schizophrenia, characterised by persistent pri-
mary negative symptoms.17,18 Other studies, reviewed by Gillespie 
et al,19 have concluded that treatment-resistant schizophrenia might 
be categorically distinct from treatment-responsive schizophrenia.
Evidence from many treatment trials, reviewed by Barry et al,20 
indicates that negative symptoms tend to be poorly responsive to 
treatment. However, we found in our very large patient sample that 
positive and negative symptoms reduced to a similar degree during 
treatment. An issue that must be considered is the characteristics of 
the patient sample, including selection criteria. It is illustrative to 
compare our findings with Tollefson et al21 in a trial of olanzapine 
compared with haloperidol in a large sample of approximately 2000 
patients. (Although the focus of Tollefson et al study was on the 
differences between responses to the two different antipsychotics, 
those differences were small and for the purpose of this discussion 
the differences between the antipsychotics is of limited relevance.) 
Tollefson et al reported a reduction of six points in PANSS negative 
symptom scores after 6 weeks of treatment with olanzapine and five 
points after 6-weeks treatment with haloperidol. We found a reduc-
tion in PANSS negative symptom scores of 8.2 points in MEP and 
8.3 points in FEP cases. It is possible that the fact that we excluded 
cases with treatment resistant illness, whereas Tollefson et al did 
not, contributed to the difference in the magnitude of the reduction 
produced by antipsychotics. In addition, it is possible that social, 
cultural or ethnic influences contributed to the greater reduction in 
negative symptoms in our sample. We discuss this in greater detail 
in the Data supplement in the ‘Social, cultural and ethnic influences 
on response to treatment’ section.
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discrete. Instead, a continuous distribution of the negative symptom 
scores from 1 to 7 across the population, as illustrated in Figs 1–4, 
needs to be considered. One way to assess patients clinically might 
be on the mean of the seven negative symptom PANSS scores, and 
clinicians may wish to consider different treatments with the graded 
distribution across the population in mind, with for example some 
findings becoming available from Lu et al (in preparation).16
The finding that the main difference in the PANSS scores of differ-
ent patients is in the extent of the negative symptoms is of considerable 
interest. If a k-means analysis is performed using only the values of 
the negative symptoms, then three population communities are found 
which differ in the mean value of the negative symptoms (Figs S4 and 
S11). This adds to the evidence that the values of the negative symptom 
scores are an important factor in producing different sub-populations 
or communities, and moreover that what distinguishes these com-
munities includes a difference in the mean negative symptom scores. 
Furthermore, the evidence in the Data supplement indicates that the 
negative symptoms are independent of the positive and general symp-
toms (i.e. the correlations between these symptoms pre-treatment is 
close to zero), so that there must be at least two partly independent 
underlying brain processes that are involved.
Subtypes of schizophrenia are no longer included in DSM-5, 
and this large study with unmedicated patients is of interest in that 
context, for no highly discrete subtypes of patients were detected 
in this study, but instead there was a continuous distribution of the 
mean value of the negative symptoms in both the FEP and MEP 
populations. The subtypes of symptoms illustrated in Figs S1, S5, 
S8 and S12 do show how a modern community detection algorithm 
clusters together different symptoms, with one symptom commu-
nity including, for example, most of the positive symptoms, and a 
second community including most of the negative symptoms.
The present investigation adds to previous analyses of subtypes of 
schizophrenia (e.g.11,24–26) by using a very much larger sample of pa-
tients (2567) than in any previous investigation; by investigating the 
symptoms in the same patients in both the unmedicated and med-
icated states; by comparing the symptoms in FEP and MEP and by 
including a more powerful machine learning, community detection, 
approach. This investigation differs from the analysis of a partly over-
lapping FEP patient population by Lu et al (in preparation)16 in that 
we used here the same participants unmedicated and medicated to 
understand the effects of the medication, which may produce clearer 
results than comparing two different groups when unmedicated or 
not; in the use of more classical clustering approaches to define how 
the symptoms cluster and how the members of the population clus-
ter; and in the emphasis on the continuous unimodal distribution of 
the negative symptoms which differs between individuals, instead 
of focusing on communities that are thought to be distinct because 
they have been categorised separately by a community detection al-
gorithm which looks for distinct communities.15
Apart from the large sample size in this study, a strength is that 
the patients came from several centres, and that similar results were 
obtained from the different centers.16 Another strength is assess-
ment of the PANSS when unmedicated and after 6 weeks of medi-
cation in the same patients. Several limitations may be mentioned. 
PANSS data were used to identify the communities in the present 
investigation and the communities may become further refined 
when further measures of differences between patients are included. 
Some PANSS items, such as difficulty in abstract thinking (N5) and 
poor attention (G11), include what may be different aspects of im-
poverished and disorganised thinking within single items, and sep-
arate assessment might lead to a richer categorisation.7,27 Further we 
suggest that the classification of possible subtypes of schizophrenia 
could be enhanced by also including information from functional 
neuroimaging and from genetics.
In conclusion, in a very large sample of cases of schizophrenia, 
we have demonstrated that variation in the negative symptoms is 
an important aspect of the variation between patients with schizo-
phrenia. The severity of the negative symptoms has a continuous 
unimodal distribution supporting a dimensional description of 
the heterogeneity of the illness, at least with respect to the negative 
symptoms. Furthermore, in this sample from which treatment re-
sistant cases were excluded, the severity of the negative symptoms 
decreased substantially during 6 weeks of antipsychotic treatment 
in both FEP and MEP cases.
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Overview 
This Supplementary material presents further details of the results in the main paper, in some cases using 
a modern community detection method for separating patients into different “subtypes”, subpopulations, 
clusters, or communities. The community detection method used is that described by Le Martelot and Hankin 
(1), using the algorithm fast_mo.m. This is described below, as is a small modification intended to help the 
community detection deal better with negative values in the correlation matrix, though with the current dataset 
it was found that this modification made little or no difference. The modified code, fast_mo.sgn.m (2) is 
available on request to the corresponding author. The community detection method used here is essentially 
that of Le Martelot and Hankin (1). 
 
Community detection algorithm for graphs with negative weights 
 The community detection algorithm is based on the idea of modularity as described by Newman and 
Girvan (3) and a modification by Traag and Bruggeman (4) which takes the negative edges into consideration. 
In the present context, details of which are provided elsewhere (2), a negative edge might be a negative 
correlation between a pair of symptoms in a symptoms cross-correlation matrix, or between a pair of 
individuals in the population cross-correlation matrix. Consider a weighted graph G = [V, E, W] with V the 
node set, E the edge set and W = [𝑤𝑤𝑖𝑖𝑖𝑖]𝑖𝑖,𝑖𝑖∈𝑉𝑉 the weight matrix. In detail, an edge from node i to node j exists, 
namely, e(i, j) ∈ E if and only if 𝑤𝑤𝑖𝑖𝑖𝑖 ≠ 0. Here, we consider a symmetrical graph, i.e., W is a symmetrical 
matrix. We emphasize that this method can be extended to directed graphs with asymmetrical weights easily. 
Consequently, the graph G can be divided into two graphs: 𝐺𝐺+ and 𝐺𝐺−, which comprise the same node set 
V, the positive/negative edge subsets, and the positive/negative weight matrices respectively. Both positive and 
negative edges are considered. Thus, the edge set E is divided into two subsets: the positive edge subset 𝐸𝐸+ ={e(i, j) ∈ E: 𝑤𝑤𝑖𝑖𝑖𝑖 > 0}  and the negative edge subset  𝐸𝐸− = {e(i, j) ∈ E: 𝑤𝑤𝑖𝑖𝑖𝑖 < 0} . Thus, define the positive 
weighted degrees and negative weighted degrees of each node as follows respectively 
𝑘𝑘𝑖𝑖
+ = � 𝑤𝑤𝑖𝑖𝑖𝑖
𝑒𝑒(𝑖𝑖,𝑖𝑖)∈𝐸𝐸+ , 𝑘𝑘𝑖𝑖− = � 𝑤𝑤𝑖𝑖𝑖𝑖𝑒𝑒(𝑖𝑖,𝑖𝑖)∈𝐸𝐸− , i ∈ V 
Essentially, nodes in the same community have more positive edges and fewer negative edges than nodes 
between communities. The extended modularity is the sum of the differences between the fraction of edge 
weights that fall within communities, minus the expected value of the same quantity if edges fall as random 
graphs, considering the positive and negative edges, without regard for the community structure, as given in 
Equation (1) (4): 
𝑄𝑄𝑀𝑀(𝑊𝑊, 𝛿𝛿) = 12𝑚𝑚 � [𝑤𝑤𝑖𝑖𝑖𝑖 − �𝑝𝑝𝑖𝑖𝑖𝑖+ − 𝑝𝑝𝑖𝑖𝑖𝑖−�] ∙ 𝛿𝛿(𝑖𝑖, 𝑗𝑗)
𝑖𝑖,𝑖𝑖∈𝑉𝑉 .                   (1) 
Here m is the total of the absolute values of the weighted matrix W, the community structure function 
δ(i, j)returns one if nodes i and j belong to the same community, and zero otherwise (5), and 𝑝𝑝𝑖𝑖𝑖𝑖± stands for 
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the coupling probability from node i to node j in random graphs that follows the same weight distribution in 
𝐺𝐺± resepectively. In detail 
𝑝𝑝𝑖𝑖𝑖𝑖
+ = 𝑘𝑘𝑖𝑖+𝑘𝑘𝑗𝑗+
𝑚𝑚+
,𝑝𝑝𝑖𝑖𝑖𝑖− = 𝑘𝑘𝑖𝑖−𝑘𝑘𝑗𝑗−𝑚𝑚−   
where 𝑚𝑚± are the sum of the absolute values of the weighted matrices of the positive and negative graph 
𝐺𝐺± respectively. The higher the value of 𝑄𝑄𝑀𝑀, the better is the community division. 
 Given the number of communities, denoted by κ, the fast community detection algorithm that we used 
(1) starts with a state in which each vertex is randomly organized into κ communities (1). (The Matlab code 
‘fast_mo.m’ that we used in this study was downloaded from 
http://www.elemartelot.org/index.php/programming/cd-code, and was modified to work as described here with 
negative edges.) We repeatedly change the community label of each vertex (in a random order) and choose at 
each step the join that results in the greatest increase in 𝑄𝑄𝑀𝑀 until no improvement occurs. This process is 
repeated 100 times and the best result (with the largest 𝑄𝑄𝑀𝑀) is taken  (1). We take different values of k and 
repeat this algorithm and detect the community structure with the largest 𝑄𝑄𝑀𝑀  over different numbers of 
communities. It is noted that the community method can subtract the background noise in the 𝑄𝑄𝑀𝑀 function, 
and this makes it potentially more robust and accurate than classical clustering methods, for instance, k-means. 
In comparison to the original fast_mo algorithm (1) in which the number of communities is calculated in an 
unsupervised way by a hierarchical clustering method, both community structures that have intersections but 
local maximum values of 𝑄𝑄𝑀𝑀 can be probed by our algorithm (fast_mo_sgn) (2) but may be missed by that 
fast_mo (1). 
 
The disagreement between two community structures, 𝛿𝛿1(∙,∙) and 𝛿𝛿2(∙,∙), is measured as follows (2): 
dis(𝛿𝛿1,𝛿𝛿2) = 1𝑁𝑁(𝑁𝑁 − 1)/2�𝐶𝐶𝛿𝛿1,𝛿𝛿2(𝑖𝑖, 𝑗𝑗)
𝑖𝑖>𝑖𝑖
 
 with 
𝐶𝐶𝛿𝛿1,𝛿𝛿2(𝑖𝑖, 𝑗𝑗) = �1 𝛿𝛿1(𝑖𝑖, 𝑗𝑗) = 𝛿𝛿2(𝑖𝑖, 𝑗𝑗)0 𝛿𝛿1(𝑖𝑖, 𝑗𝑗) ≠ 𝛿𝛿2(𝑖𝑖, 𝑗𝑗) 
 where 𝑁𝑁 stands for the number of the nodes in the graph. 
 
Participants – further details 
 Two samples comprising a total of 2,567 patients with schizophrenia were diagnosed according to DSM-
IV criteria (6) and the symptoms were assessed using the Positive and Negative Syndrome Scale for 
Schizophrenia (7). The first study sample included 687 first-episode, drug-naïve patients (FEP) with 
schizophrenia. The second study sample included 1880 multi-episode patients (MEP) with schizophrenia 
BJPO/2017/005058, doi: 10.1192/bjpo.bp.117.005058 
 
4 
recruited from inpatients at the same centers. The patients were recruited from inpatients and outpatients from 
the mental health departments of four institutes: the Sixth Hospital of Peking University, the Second Xiangya 
Hospital of Central South University, Beijing Anding Hospital, and Beijing HuiLongGuan Hospital with 
institutional approval of the investigation and informed consent of the patients.  
 
 Patients entered the study according to the following criteria: 1) 18-45 years old; 2) Han Chinese 
descendants; 3) a diagnosis of schizophrenia, using the Structured Clinical Interview of the DSM-IV (SCID); 
4) physically healthy and had all laboratory parameters within normal limits; 5) total score of the PANSS at 
baseline was more than 60, and at least 3 positive items were scored more than 4. The consensus diagnoses 
were made by at least two experienced psychiatrists on the basis of structured interviews (SCID) with patients 
and families and review of medical records. The training of the psychiatrists for this investigation included 
training in research protocols, standard diagnostic criteria, and other scales for assessment of symptoms and 
side effects, as well as videos for standardized scale assessment. The specific training took ten days. The 
PANSS was administered by the psychiatrists. The MEP patients had several previous episodes of 
schizophrenia, with the average duration of the illness 7.97 years. 
Patients were excluded using the following criteria: 1) a diagnosis of schizoaffective disorder, mental 
retardation, or other cognitive disorders; 2) a history of serious adverse reactions to the proposed treatments; 
3) a history of treatment resistance, defined by the persistence of severe symptoms despite adequate trials of 
one of the proposed treatments or prior treatment with clozapine; 4) pregnant or breast-feeding; 5) a serious 
and unstable medical condition. The dropout rate was 11.99%. 
 
 
RESULTS with the community detection analysis 
 
MEP group 
We start with the Multi-Episode (MEP) group, as this is the larger group, with 1880 patients with 
multiple episode schizophrenia, allowing very robust statistical analysis. We start with the pretreatment results 
when no medication was present (MEP_Pre). 
MEP_Pre 
Fig. 1a of the main paper shows the MEP_Pre symptom correlation matrix. The community detection 
method detected four symptom communities, as illustrated in Fig. S1. Symptom community 4 included the 
majority of the positive symptoms (P1 P4 P5 P6 P7) and G8 G9 G12 G14. Symptom community 1 included 
the majority of the negative symptoms (N1 N2 N3 N4 N6) and G7 G13 G16. Symptom community 2 included 
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conceptual disorganization (P2), difficulty with abstract thinking (N5), stereotyped thinking (N7) together with 
several general symptoms (G5 G10 G11 G15) that largely reflect disorganized behavior. Symptom community 
3 comprised P3 (hallucinatory behaviour) together with 5 affective symptoms, G1 G2 G3 G4 G6. Note that 
the order of the symptoms along the axes has been reordered to reflect the communities detected. 
Fig. S2 shows the three patient subpopulation clusters that were detected with the community detection 
algorithm, with 770, 318, and 792 patients in each cluster. It is evident that the negative symptoms (8-14) differ 
between the 3 patient groups, with population 1 having the highest scores for the Negative symptoms, 
population 2 intermediate scores, and population 3 the lowest scores. 
Fig. S3 shows the average symptom values in the three patient clusters for the MEP_Pre group using 
the community detection algorithm. The group labelled PN (positive and high negative symptoms) had high 
values for the negative symptoms N1-N7 = symptoms 8-14). The group labelled Pn (positive and intermediate 
negative symptoms) had intermediate values for the negative symptoms. The group labelled P (positive and 
low negative symptoms) had low values for the negative symptoms, especially N1 and N2. Little else differed 
between these clusters, except that the PN cluster has a higher value for P2 (symptom 2, conceptual 
disorganization), and smaller value for P6 (symptom 6, suspiciousness/persecution); and the P cluster had 
relatively high scores on P1, P3-P7, and symptoms 22 and 23 namely G8 (uncooperativeness) and G9 (unusual 
thought content). A comparison of Fig. 1b and Fig. S3 shows that the community detection method (Fig. S3) 
produced almost the same mean values for the symptoms of the three groups as the k-means analysis (Fig. 1b), 
although the numbers of patients in each group were somewhat different. Further, the separation into different 
populations reflected the mean values of the negative symptoms, which were for community P 2.63, for Pn 
2.93, and for PN 3.86. 
Fig. S4 shows the community detection results based only on the 7 negative symptoms. Again, three 
populations were detected, which differed in having values for the negative symptoms that were high (PN), 
intermediate (Pn), or low (P). The fact that the community detection method found three populations when 
only the negative symptoms were considered (the same number as when all the symptoms were considered, 
see Figs. S2 and S3) strengthens the evidence that an important factor in determining how the populations san 
be separated lies in the values of the negative symptoms. 
MEP_Post 
We now consider the multiepisode patients in the post-treatment, medicated, state (MEP_Post). The 
rationale for the different analyses has been described for the MEP_Pre group, and the remainder of the 
analyses are presented succinctly. 
Fig. S5 shows the MEP_Post symptom correlation matrix rearranged according to the 4 communities 
detected. Community 4 included all the positive symptoms, and community 1 the majority of the negative 
symptoms. In this medicated states, the positive symptoms form a more uniform cluster than in the 
unmedicated state where positive symptoms were included in several different communities. The same is the 
case for the negative symptoms in the medicated state.  
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Fig. S6 shows the three subpopulation clusters in the MEP_post dataset that were detected with the 
community detection algorithm, with the number of patients in the three clusters as follows; PN=921, Pn = 19, 
and P= 940. Of course these post-treatment subpopulation analyses did not necessarily place the same patients 
in the three groups that were detected pre-treatment, and indeed the interpretation of these analyses is that even 
post-treatment, the main factor that enables patients to be separated into 3 subpopulations is the magnitude of 
the negative symptoms. 
Fig. S7 shows the average symptom values in these three patient clusters for the MEP_Post group. The 
group labelled PN (positive and high negative symptoms) had high values for the negative symptoms N1-N7 
= symptoms 8-14). The group labelled Pn (positive and intermediate negative symptoms) had almost as high 
values for the negative symptoms, and lower values for the positive symptoms. The group labelled P (positive 
and low negative symptoms) had low values for the negative symptoms. A comparison of Fig. 1c and Fig. S7 
shows that the community detection method (Fig. S7) produced almost the same mean values for the symptoms 
of the three groups as the k-means analysis (Fig. 1c), although the numbers of patients in each group were 
different, and the Pn group was less different from the PN group with the community detection method (Fig. 
S7) than the k-means method (Fig. 1c). 
 
FEP group 
We now analyse the data from the first episode group of patients with schizophrenia (the FEP group), 
with 687 patients, using the community detection method. We start with the pretreatment results (FEP_Pre). 
FEP_Pre 
Fig. S8 shows the FEP_Pre symptom correlation matrix rearranged by the 4 main communities 
detected with community detection. Community 2 included the majority of the negative symptoms but also P2 
(conceptual disorganization), and community 1 the majority of the positive symptoms. Comparison with the 
MEP_Pre case (Fig. S1) shows that in the FEP-Pre patients, the positive symptoms are more within the same 
community, as are the negative symptoms. 
Fig. S9 shows the three population communities that were detected, with 264, 136, and 287 patients 
in each cluster. The order of the populations in this Figure is PN, Pn, then P. 
Fig. S10 shows the average symptom values in the three patient clusters for the FEP_Pre group. A 
comparison of Fig. 3a and Fig. S10 shows that the community detection method (Fig. S10) produced almost 
the same mean values for the symptoms of the three groups as the k-means analysis (Fig. 3a), although the 
numbers of patients in each group were a little different, and there was a small difference in P3 and P4. Further, 
the separation into different populations reflected the mean values of the negative symptoms, which were for 
community PN 3.77, for Pn 3.22, and for P 2.34. 
To analyze whether there are communities of patients when just the negative symptom scores are 
considered (N1-N7), the community detection analysis was repeated using only the scores for N1-N7. The 
results in Fig. S11 show that three clusters are found: one with all the negative symptoms high (PN); one with 
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most high apart from N4 and N5 (Pn); and a third community of patients with low values for most of the 
negative symptoms (P). The fact that the community detection method found three populations when only the 
negative symptoms were considered (the same number as when all the symptoms were considered, see Figs. 
S9 and S10) strengthens the evidence that an important factor in determining how the populations can be 
separated lies in the values of the negative symptoms.  
 
FEP_Post 
We now consider the first episode patients in the post-treatment, medicated, state (FEP_Post). 
Fig. S12 shows the FEP_Post symptom correlation matrix rearranged by the 4 communities detected 
with community detection. Symptom community 1 included all the positive symptoms, and community 2 all 
of the negative symptoms.  
Fig. S13 shows the three population communities that were detected, with 282, 242, and 163 patients 
in each community PN, Pn, and P. 
Fig. S14 shows the average symptom values in the three patient clusters for the FEP_Post group. A 
comparison of Fig. 3c and Fig. S14 shows that the community detection method (Fig. S14) produced almost 
the same mean values for the symptoms of the three groups as the k-means analysis (Fig. 3c), although the 
numbers of patients in each group were somewhat different. 
Discussion of Community detection results  
The analyses with the community detection methods described separated each population, MEP and FEP, 
into three subpopulation communities. The mean values of the symptoms in these subpopulation communities 
were very similar to, indeed almost identical to, those shown in the main paper that were identified with k-
means clustering. Moreover, this applied to both groups of patients, MEP and FEP, both when unmedicated 
and when medicated. Moreover, fast-mo_sgn, designed to facilitate the analysis of correlation matrices with 
some negative correlation (2), in practice with the data analyzed here produced essentially the same 
classification as fast_mo (1). An implication is that community detection is not providing something with this 
dataset that is conceptually different and goes beyond what k-means shows, though an advantage of the 
community detection approach used is that it does identify an optimal number of clusters into which to classify 
the data.  
Interestingly, the community detection method when applied to the symptom correlation matrix identified 
in most cases four symptom communities, with the majority of the negative and of the positive symptoms in 
separate communities, but clustered with some of the general symptoms (Figs. S1 and S8). In both patient 
groups, both before and after treatment there was an ‘affective’ symptom community dominated by symptoms 
of depression and anxiety: somatic concern G1; anxiety G2; guilt G3; tension G4 and depression G6. 
(Community 2 in MEP-Post; and community 3 in MEP-Pre, FEP-Pre and FEP-Post). In the FEP-Pre group, 
hallucinations are also included in community 3.  Furthermore, in the MEP-Pre group, the other community 
(2, see Fig. S1) was dominated by symptoms reflecting disorganization of thought and behavior, together with 
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cognitive dysfunction: Conceptual disorganization P2; Difficulty in abstract thinking N5; Stereotyped thinking 
N7; Mannerisms and posturing G5; Disorientation G10; Poor attention G11; and Preoccupation G15. A similar 
community was identified in the FEP-Pre group (Fig. S8). Further analyses for both the MEP and FEP group 
prior to treatment showed that the mean of the negative symptoms was not correlated with either the affective 
group of symptoms, or the depression score (G6) (r in all cases ≤ 0.05, ns), nor indeed with the mean positive 
symptom score for P1 and P3-P7 (r<0.1, ns). 
 
Comparison with bipartite classification 
The community detection method used in this Supplementary Material did not include the bipartite 
clustering approach that utilizes both the correlations in the populations and the correlations in the symptoms 
being developed by Lu et al in preparation (2) in an analysis of a partly overlapping dataset.  The present 
results provide an analysis that adopts a more usual community detection approach (1). Further, we note that 
the datasets are different in this study and that analysed by Lu et al (2) in that in the present study the same 
FEP patient set was analysed pre- and post-medication, to enable a direct comparison, and also in that the Lu 
et al (2) investigation had no MEP dataset, and the MEP dataset is very large. 
The results obtained with the community detection methods, using fast_mo_sgn.m modified from 
fast_mo.m (1) with bipartite clustering based on both the population and the symptom distributions are 
described elsewhere (2). We note that the bipartite analysis detected only two patient communities for the FEP 
group, whereas the same community detection algorithm fast_mo_sgn but without bipartite analysis detected 
3 communities as described here. Apart from that difference, the bipartite classification separated the 
populations on a similar basis, with the means between the different communities reflecting largely differences 
in the Negative symptoms (2). Further, the bipartite categorization sometimes found 3 patient groups for the 
FEP_Pre group, the Q value indicating the optimality of the solution was very similar when the bipartite 
method found 2 and when it found 3 groups. 
 
Factor analysis and multidimensional scaling on the symptom correlation matrices 
 To provide further insight into how the different PANSS symptoms are related to each other, and how 
they separate from each other, factor analyses and multidimensional scaling were performed on the symptom 
correlation matrices. The functions available in Matlab were used. 
Fig. S15 shows the results of factor analysis on the MEP pretreatment symptom correlation matrix. This 
shows that most of the negative symptoms contribute to factor 1; that most of the positive symptoms contribute 
to factor 2; and that some of the general symptoms, most notably the affective symptoms, G1,G2,G3,G4 and 
G6, contribute to factor 3. In that factor 1 relates to the greatest amount of variance, this provides further 
evidence that variation in the negative symptoms are the major source of variation between individuals with 
schizophrenia. This was confirmed with principal component analysis, which showed that the first principal 
component accounted for 16.7% of the variance, with the second 11.4%, and the third 7.4%. 
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Fig. S16 shows the results of multidimensional scaling on the MEP pretreatment symptom correlation 
matrix. The distances in this 2D space reflect how similar each symptom is to the others, assessed across the 
whole population of patients (8). This shows that most of the negative symptoms are grouped close together 
in one part of the space; that most of the positive symptoms are in a different part of the space, apart from P2 
which is placed towards the Negative symptoms; and that some of the general symptoms including the affective 
symptoms, are separate from the Negative and Positive symptoms, while other general symptoms are close to 
either negative or Positive symptoms. This Figure provides considerable insight into the relation between the 
different symptoms. 
Fig. S17 shows the results of factor analysis on the FEP pretreatment symptom correlation matrix. This 
shows that most of the negative symptoms contribute to factor 1; that most of the positive symptoms contribute 
to factor 2; and that some of the affective general symptoms contribute to factor 3. In that factor 1 relates to 
the greatest amount of variance, this provides further evidence that variation in the negative symptoms are the 
major source of variation between individuals with schizophrenia. This was confirmed with principal 
component analysis, which showed that the first principal component accounted for 18.8% of the variance, 
with the second 10.8%, and the third 7.4%. 
Fig. S18 shows the results of multidimensional scaling on the FEP pretreatment symptom correlation 
matrix. This shows that most of the negative symptoms are grouped close together in one part of the space; 
that most of the positive symptoms are in a different part of the space, apart from P2 which is placed towards 
the Negative symptoms; and that some of the general symptoms are separate from the Negative and Positive 
symptoms, while other general symptoms are close to either negative or Positive symptoms. This Figure 
provides considerable insight into the relation between the different symptoms. 
In general, the distances between the symptoms are similar for the MEP and FEP populations, as 
illustrated in Figs. S17 and S18. Further, the MDS spaces were similar before treatment as illustrated and after 
treatment (not illustrated). 
 
Comparison of MEP and FEP groups 
It is evident from Fig. 5 that in the pre-treatment condition, the FEP and MEP groups had almost identical 
scores, and this is confirmed by the explicit comparison shown in Fig. S19. It is evident from Fig. 5 that in the 
post-treatment condition, the FEP and MEP groups had almost identical scores (though lower than in the pre-
treatment groups), and this is confirmed by the explicit comparison shown in Fig. S20. 
 
The negative symptoms of schizophrenia, and the effects of medication 
In the results described here, medication reduced the negative symptoms of schizophrenia. This reduction 
might have been a direct effect of the medication on the negative symptoms, or it might have been an effect 
secondary to the reduction of the positive symptoms, or indeed, of some of the other symptoms. The following 
analyses were performed to assess this. 
BJPO/2017/005058, doi: 10.1192/bjpo.bp.117.005058 
 
10 
First, it was found that there was no correlation in the unmedicated state between the positive symptoms 
of schizophrenia (the mean of P1, and P3-P7) and the negative symptoms (the mean of N1-N7) before 
medication (FEP group r=-0.03, n=687; MEP group r=0.06, n=1880). After 6 weeks of medication, there was 
a correlation in the same individuals between the positive symptoms of schizophrenia and the negative 
symptoms (FEP group r=0.60, n=687; MEP group r=0.42, n=1880). These findings are consistent with either 
hypothesis: that the reduction of positive symptoms might have been a direct effect of the medication; or that 
the reduction of negative symptoms was related at least in part to the reduction in the positive symptoms. 
Further, there was a correlation between the negative symptoms when unmedicated and when medicated (FEP 
group r=-0.03; MEP group r=0.62). To assess whether the medication had an effect on the negative symptoms 
that was independent of the effect of the medication on the positive symptoms, an analysis of covariance 
(ANCOVA) was performed, using medication as the independent variable, the mean of the negative symptoms 
for each individual as the dependent variable, and the mean of the positive symptoms for each individual as 
the covariate. For the FEP group, there was a significant effect of the medication on the negative symptoms 
after controlling for the effect of the positive symptoms, F(1,1371) = 33.6, p<0.001. There was also a 
significant effect of the medication on the positive symptoms, F(1,1371) = 87.7, p<0.001). For the MEP group, 
there was a significant effect of the medication on the negative symptoms after controlling for the effect of the 
positive symptoms, F(1,3757) = 121.8, p<0.001. There was also a significant effect on the positive symptoms, 
F(1,3757) = 200.0, p<0.001). (Adding the additional covariate of the ‘affective’ symptoms described next 
made little difference to these results.) The correlation between the reduction of the negative symptoms and 
the reduction in the positive symptoms was 0.47 (p=1.9x10-38) for the FEP group and 0.44 (p=1.7x10-91) for 
the MEP group. 
The correlations of the negative symptoms with a group of symptoms sometimes described as ‘affective’, 
G1-G4 and G6, were also assessed. There was no correlation in the unmedicated state between these ‘affective’ 
symptoms of schizophrenia and the negative symptoms (FEP group r=0.05; MEP group r=0.008). After 6 
weeks of medication, there was a correlation in the same individuals between the ‘affective’ symptoms of 
schizophrenia and the negative symptoms (FEP group r=0.26, n=687; MEP group r=0.22). However, in an 
ANCOVA, using the affective symptoms as a covariate had little effect of the highly significant effect of the 
medication on the negative symptoms. There was a highly significant effect of the medication on the affective 
symptoms even when the negative symptoms were used as a covariate (MEP group F(1,3757) = 286.0, 
p<0.001), and interestingly this effect disappeared when the positive symptoms were instead used as the 
covariate. The correlation between the reduction of the negative symptoms and the reduction in the affective 
symptoms was 0.37 (p=1.2x10-23) for the FEP group and 0.21 (p=1.1x10-20) for the MEP group. 
We also tested whether the 3 patient communities detected using all 30 symptoms showed differences in 
the effects of treatment. The reductions in the negative symptoms were similar in the different population 
subgroups, taking into account that the means for the different subpopulations were different. For the MEP 
group the medication reduced the mean of the negative symptoms for the PN community (n=770) from 3.86 
by 1.17 ± 0.85 (mean ± standard deviation) p=9.1x10-154; for the Pn community (n=318) from 2.93 by 0.72 ± 
0.85 p=4.8x10-36; and for the P community (n=792) from 2.63 by 0.69 ± 0.65 p=2.1x10-65. For the FEP group 
the medication reduced the mean of the negative symptoms for the PN community (n=264) from 3.77 by 1.15 
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± 0.98 (mean ± standard deviation) p=1.5x10-39; for the Pn community (n=136) from 3.23 by 1.12 ± 0.77 
p=1.9x10-35; and for the P community (n=287) from 2.34 by 0.66 ± 0.65 p=4.7x10-24.  
To provide further information about the negative symptoms, the correlations between the different 
negative symptoms for the MEP group (see Fig. 1) are shown here, arranged in order N1 to N7 for the 
unmedicated state: 
     N1           N2           N3           N4           N5           N6           N7         
N1   1.00          0.73          0.50          0.61          0.32          0.47          0.31 
N2   0.73          1.00          0.47          0.68          0.36          0.45          0.35 
N3   0.50          0.47          1.00          0.50          0.32          0.58          0.19 
N4   0.61          0.68          0.50          1.00          0.33          0.48          0.30 
N5   0.32          0.36          0.32          0.33          1.00          0.40          0.50 
N6   0.47          0.45          0.58          0.48          0.40          1.00          0.30 
N7   0.31          0.35          0.19          0.30          0.50          0.30          1.00 
 
To provide further evidence on whether the negative symptoms could be separated into different 
‘subtypes’, the community detection algorithm was run on the correlations shown above between the negative 
symptoms. For the MEP group, the community detection algorithm fast_mo_sgn placed the negative 
symptoms N1 (blunted affect), N2 (emotional withdrawal), and N4 (Passive/apathetic social withdrawal) into 
one community; N3 (poor rapport) and N6 (Lack of spontaneity and flow of conversation ) into a second 
community; and N5 (), Difficulty in abstract thinking) and N7 (Stereotyped thinking) into a third community, 
with a value of Q of 0.160. The bases for this categorization can be seen in the correlation matrix. This can be 
compared with a recent overview which divided the negative symptoms into one cluster with blunted affect 
and alogia, and a second cluster with anhedonia, avolition and asociality (9). (Alogia is reduction in the 
quantity of speech and in its spontaneous elaboration.) 
 The correlations between the different negative symptoms for the FEP group (see Fig. 3) are shown 
here, arranged in order N1 to N7 for the unmedicated state: 
     N1           N2           N3           N4           N5           N6           N7           
N1   1.00          0.75          0.55          0.69          0.35          0.53          0.31 
N2   0.75          1.00          0.51          0.72          0.38          0.44          0.36 
N3   0.55          0.51          1.00          0.55          0.36          0.61          0.25 
N4   0.69          0.72          0.55          1.00          0.38          0.52          0.33 
N5   0.35          0.38          0.36          0.38          1.00          0.44          0.47 
N6   0.53          0.44          0.61          0.52          0.44          1.00          0.32 
N7   0.31          0.36          0.25          0.33          0.47          0.32          1.00      
For the FEP group, the community detection algorithm fast_mo_sgn placed the negative symptoms N1, N2, 
and N4 into one community; N3 and N6 into a second community; and N5 and N7 into a third community, 
with a value of Q of 0.143. 
 In terms of the effects of medication, these were similar across these three negative symptom 
communities. The mean of the 7 negative symptoms when unmedicated was 3.06, when medicated was 2.14, 
with a reduction of 0.92 (p=4x10-65). The mean of the community 1 negative symptoms when unmedicated 
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was 3.25, when medicated was 2.32, with a reduction of 0.93 (p=3x10-48). The mean of the community 2 
negative symptoms when unmedicated was 3.36, when medicated was 2.22, with a reduction of 1.13 (p=6x10-
70). The mean of the community 3 negative symptoms when unmedicated was 2.49, when medicated was 1.79, 
with a reduction of 0.70 (p=7x10-32). 
 Further, in terms of the effects of medication, the medication produced similar decreases in all the 
symptoms in the pre-medication identified PN, Pn, and P subpopulations of both the MEP and the FEP groups, 
as illustrated in Figs. S21 and S22, with the actual reduction as expected influenced by how high the score for 
each symptom was in the pre-medication state.  
Overall, our findings indicate that some but clearly not all of the variance between patients in the response 
of the negative symptoms to medication can be accounted for by change in the positive symptoms but not by 
change in the affective symptoms. This is consistent with the possibility that the negative symptoms in our 
sample are in part secondary, in the sense that they arise as a reaction to positive symptoms, but it is also 
possible that the shared variance in treatment response reflects a shared primary effect of the medication on 
the mechanisms that produce the different symptoms. In any case, the effects of the medication on the negative 
symptoms are not largely accounted for by changes in the positive symptoms, as shown by the results of the 
ANCOVAs. This interpretation is consistent with the interpretation (10, 11) that the positive correlation 
between response of positive and negative symptoms to antipsychotics supports the hypothesis that different 
symptom domains in schizophrenia may depend on each other through a unified upstream pathological disease 
process. But at the same time, our findings show that the effects of the medication on the negative symptoms 
are to a considerable extent independent of the effects of the medication on the positive symptoms, so that it 
is likely that there are at least partly independent mechanisms for the positive and negative symptoms. 
The evidence that an appreciable proportion of the variance in treatment response of negative symptoms 
can be accounted for by variance in response of positive symptoms suggests that the causes of negative 
symptoms are not homogeneous. In particular, it is consistent with the possibility that some negative symptoms 
are secondary to the positive symptoms. PANSS ratings do not distinguish primary from secondary negative 
symptoms. Nor do they attempt to distinguish transient negative symptoms for persistent negative symptoms. 
Thus, the findings of our study neither confirm nor refute the proposal a minor proportion of cases of 
schizophrenia suffer from the discrete type of schizophrenia characterized by persistent, primary negative 
symptoms which Kirkpatrick and colleagues have called Deficit Schizophrenia (12-14). However, the present 
results do show that in the unmedicated state, there is no correlation between the positive and negative 
symptoms across large populations of patients; and that medication introduces a correlation between the 
negative and the positive symptoms. 
There is also discussion in the literature of whether there are subtypes of patients with different negative 
symptoms (that is, separate categories of patients); or whether a dimensional view is more appropriate (with 
continuous variation of the negative symptoms across the population) (15-17). The present results are relevant 
to this, for they show a continuous distribution of the negative symptoms across both the FEP and MEP 
populations with a unimodal not bimodal or multimodal distribution (Figs. 2 and 4). The present results thus 
support a dimensional interpretation of the differences in the negative symptoms between individuals with 
schizophrenia. Consistent with this, when clustering / community detection algorithms are forced to divide the 
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patients into subpopulations, the major difference between the subpopulations is in the negative symptoms, as 
shown here. Thus although algorithms such as k-means and community detection can separate data such as 
these into different subpopulations, that does not provide evidence that the subpopulations are highly distinct, 
and indeed the further analyses provided in Figs 2 and 4, and in the Supplementary material including factor 
analysis, multidimensional scaling, and analysis of the effects of the treatment in the different subpopulations, 
provide evidence that the main source of the difference between patients is in the mean of the negative 
symptoms, which has a continuous unimodal distribution, with the data this being closer to a multidimensional 
view compared to a discrete subtype view of schizophrenia. 
Social, cultural and ethnic influences on response to treatment 
As reported in the main text, we observed that negative and positive symptoms exhibited a similar 
response to treatment in both FEP and MEP cases, and furthermore that MEP and FEP cases exhibited a similar 
overall treatment response.   
One issue to consider is the potentially beneficial effects of family or social support and of cultural 
attitudes.  In an attempt to explain the better outcome of schizophrenia in non-industrialised countries 
reported in both the WHO International Pilot Study of Schizophrenia (18) and WHO Collaborative Study on 
the Determinants of Outcome of Severe Mental Disorders (19), Cooper and Sartorius (20) proposed that 
patients in non-industrialised countries might experience ‘an interpersonal environment that is characterized 
by many relationships that are potentially supportive and flexible….[and] comparatively low level of pressure 
towards differentiation and specialization in work.’ Cohen (21) has argued that even in that era, ethnographic 
studies did not support the hypothesis of Cooper and Sartorius. It is perhaps even more questionable that the 
supportive family environment proposed by Cooper and Sartorius would match that of modern-day China. 
Nonetheless, Markus and Kiayama (22) presented evidence that East Asian culture promotes a view of 
one’s self as being interconnected with members of one’s community, in contrast to Western culture that 
encourages a view of one’s self as an autonomous, independent and unique individual.   More recently, Han 
and Humphreys (23) reviewed evidence from functional brain imaging studies indicating that this cultural 
difference in the view of self is associated with differences in the function of brain regions such as medial 
frontal cortex that support cognitive and affective processes. It is plausible that cultural differences between 
East Asians and Westerners might affect brain development leading to differences in the adaptability of the 
brain circuits implicated in negative symptoms, leading to greater responsivity of negative symptoms to 
treatment.      
Ninety-five percent of the patients participating in our study lived with family or a partner. The 
participants in our study were in-patients throughout the period of the study, reducing the opportunity for 
family or social support to have a direct influence during that period. However, the evidence reviewed by Han 
and Humphreys (23) suggests that it is longstanding family and social influence that are more relevant to any 
modification of the brain circuits likely to be implicated in negative symptoms. Thus it is plausible, though 
speculative, that effects of family or social support and of cultural attitudes might have contributed to the 
relatively good treatment response of negative symptoms observed in our study.  
BJPO/2017/005058, doi: 10.1192/bjpo.bp.117.005058 
 
14 
It is also possible that genetic variations that influence pharmacokinetic or pharmacodynamic processes 
might in principle account for ethnic or racial differences in response to antipsychotics.  However, the 
evidence is inconclusive. For example, in a review of 80 clinical studies on polymorphisms in candidate genes 
that might influence neurotransmitters or receptors, Kirchheiner et al (24) did not find consistent evidence of 
significant associations between potentially relevant genotypes and either therapeutic response or adverse drug 
reactions. 
With regard to our finding that MEP cases show a similar response to FEP cases, contrary to findings in 
Western studies, one issue to consider is the possibility of differences in the proportions of patients with 
schizophrenia who are prescribed continuous treatment with antipsychotic medication. It would be expected 
that individuals who relapse while taking antipsychotic medication are less likely to respond to subsequent 
antipsychotic medication than those who relapse while not receiving medication. This might arise either 
because those relapsing while taking antipsychotics are inherently less likely to benefit from antipsychotic 
treatment, or because continuous exposure to antipsychotics might have resulted in reduced effectiveness, for 
example by altering dopamine receptor sensitivity leading to ‘supersensitivity’ psychosis (25). In our study, 
only 32.4% of the MEP cases had relapsed while receiving antipsychotic medication.  Thus, the relatively 
good treatment response in MEP cases might be at least partially explained by only a small proportion of cases 
predisposed to a poor response indicated by prior relapse while taking antipsychotic medication. 
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Fig. S1. MEP_Pre symptom correlation matrix, rearranged to show the 4 communities detected with the 
community detection algorithm. The color bar indicates the value of the Pearson correlation. The scores are 
arranged in this matrix according to the order below, where N1 of community 1 is shown as symptom 1 and 
G14 of community 4 as symptom 30. (The names provided for each community are referred to in the text.) 
Community 1: N1 N2 N3 N4 N6 G7 G13 G16. (Negative) 
Community 2: P2 N5 N7 G5 G10 G11 G15. (Disorganization of thought and behavior, and cognitive 
dysfunction). 
Community 3: P3 G1 G2 G3 G4 G6. (Affective / Depressed) 
Community 4: P1 P4 P5 P6 P7 G8 G9 G12 G14. (Positive) 
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Fig. S2. Three clusters of MEP_Pre patients detected with community detection. 
 
 
 
Fig. S3. MEP_Pre average symptom values in the three patient clusters detected by community detection. 
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Fig. S4. MEP_Pre average symptom values in the three patient clusters that were identified by k-means with 
a cosine similarity measure based only on symptoms N1 – N7. The mean of the P group was 2.50, of the Pn 
group 2.96, and of the PN group 3.87. This shows that k-means using only the negative symptoms still 
categorized the patients into communities that differed in the mean value of the negative scores. (fast_mo_sgn 
and k-means with a correlation measure was not carried out as some patients had identical scores for the 7 
negative symptoms.) 
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Fig. S5. MEP_Post symptom correlation matrix rearranged according to the 4 communities detected. The 
scores are arranged in this matrix according to the order below, where N1 is shown as symptom 1 and G14 as 
symptom 30. 
Community 1: N1 N2 N3 N4 N6 G7 G11 G13 G16.  
Community 2: G1 G2 G3 G4 G5 G6 G10. 
Community 3: N7 G15. 
Community 4: P1 P2 P3 P4 P5 P6 P7 G8 G9 G12 G14.  
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Fig. S6. Three clusters of MEP_Post patients detected by community detection.  
 
 
 
Fig. S7. MEP_Post average symptom values in the three patient clusters detected by community detection. 
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Fig. S8. FEP_Pre symptom correlation matrix rearranged by the 5 communities detected with community 
detection. The scores are arranged in this matrix according to the order below, where P1 of community 1 is 
shown as symptom 1 and G15 of community 5 is shown as symptom 30. (The names provided for each 
community are referred to in the text.) 
Community 1: P1 P3 P4 P5 P6 P7 G8 G9 G12 G14 (Positive) 
Community 2: P2 N1 N2 N3 N4 N5 N6 N7 G7 G11 G13 (Negative) 
Community 3: G2 G3 G4 G6 (Affective / Depressed) 
Community 4: G5 G10 G15 (Disorganization of thought and behavior, and cognitive dysfunction). 
Community 5: G16 
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Fig. S9. Three clusters of FEP_Pre patients detected by community detection. The clusters are 
designated as PN, Pn and P, as they differ in the negative symptoms 8-14. 
 
 
 
Fig. S10. FEP_Pre average symptom values in the three patient clusters detected with community 
detection.    
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Fig. S11. FEP_Pre average symptom values in the three patient clusters that were identified by k-means with 
a cosine similarity measure based only on symptoms N1 – N7. The mean of the P group was 2.26, of the Pn 
group 3.06, and of the PN group 3.35. This shows that k-means using only the negative symptoms still 
categorized them into communities that differed in the mean value of the negative scores. (fast_mo_sgn and 
k-means with a correlation measure was not carried out as some patients had identical scores for the 7 negative 
symptoms.) 
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Fig. S12. FEP_Post symptom correlation matrix rearranged by the 4 communities detected with the community 
detection algorithm. The scores are arranged in this matrix according to the order below, where P1 is shown 
as symptom 1 and G15 as symptom 30. 
Community 1: P1 P2 P3 P4 P5 P6 P7 G8 G9 G12 G14.  
Community 2: N1 N2 N3 N4 N5 N6 N7 G7 G11 G13 G16.  
Community 3: G1 G2 G3 G4 G6. 
Community 4: G5 G10 G15.  
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Fig. S13. Three clusters of FEP_Post patients detected with community detection. 
 
 
Fig. S14. FEP_Post average symptom values in the three patient clusters using community detection. 
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Fig. S15. Factor analysis on the MEP pretreatment symptom correlation matrix. This shows that most of the 
negative symptoms are in factor 1; that most of the positive symptoms are in factor 2; and that some of the 
general symptoms are in factor 3. 
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Fig. S16. Multidimensional scaling on the MEP pretreatment symptom correlation matrix. This shows that 
most of the negative symptoms are grouped close together in one part of the space; that most of the positive 
symptoms are in a different part of the space, apart from P2 which is placed towards the Negative symptoms; 
and that some of the general symptoms are separate from the Negative and Positive symptoms, while other 
general symptoms are close to either negative or Positive symptoms. The distances in this 2D space reflect 
how similar each symptom is to the others, assessed across the whole population of patients. 
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Fig. S17. Factor analysis on the FEP pretreatment symptom correlation matrix. This shows that most of the 
negative symptoms are in factor 1; that most of the positive symptoms are in factor 2; and that some of the 
general symptoms are in factor 3. 
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Fig. S18. Multidimensional scaling on the FEP pretreatment symptom correlation matrix. This shows that most 
of the negative symptoms are grouped close together in one part of the space; that most of the positive 
symptoms are in a different part of the space, apart from P2 which is placed towards the Negative symptoms; 
and that some of the general symptoms are separate from the Negative and Positive symptoms, while other 
general symptoms are close to either negative or Positive symptoms. The distances in this 2D space reflect 
how similar each symptom is to the others, assessed across the whole population of patients. 
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Fig, S19. Mean scores for the FEP_Pre and MEP_Pre groups. There is little difference. 
 
Fig. S20. Mean scores for the FEP_Post and MEP_Post groups. There is little difference between the groups, 
though most symptoms have decreased from the pre-treatment state. 
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Fig. S21. The reduction in each of the PANSS symptom scores the PN, Pn, and P subpopulations identified at 
the pre-medication stage for the MEP group. 
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Fig. S22. The reduction in each of the PANSS symptom scores the PN, Pn, and P subpopulations identified at 
the pre-medication stage for the FEP group. 
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